Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study - 15/01/20
, Luz Maria Medrano a , Juan Berenguer c, d , Oscar Brochado-Kith a , Juan González-García e , Ma Ángeles Jiménez-Sousa a , Carmen Quereda f , José Sanz g , María Jesús Téllez h , Laura Díaz d, i , José Luis JIménez d, j , Salvador Resino a, ⁎ the GESIDA 3603b Study Group
Highlights |
• | We evaluated the changes in the medium-term of a large number of biomarkers in HIV/HCV-patients who achieved SVR. |
• | HIV/HCV-patients showed a slight improvement in the overall profile of immune biomarkers after achieving SVR with peg-IFN-α/ribavirin. |
• | It would be necessary to evaluate whether these biomarkers approximate levels in those who never had chronic hepatitis C. |
Résumé |
Objective |
There are a lack of consistency among articles in regards to the evolution of peripheral immune biomarkers after HCV therapy. We aimed to detect the most relevant changes in peripheral immune biomarkers among HIV/HCV-coinfected patients who achieved sustained virologic response (SVR) following peg-IFN-α/ribavirin therapy and to evaluate its normalization with respect to an HIV-monoinfected control group.
Methods |
We performed a prospective cohort study in 99 HIV/HCV-coinfected patients with samples at baseline (HIV/HCV-b-group) and at week 24 after SVR (HIV/HCV-f-group). We also used a control group of 39 HIV-monoinfected patients (HIV-group) negative for HCV and HBV infections, and who had undetectable HIV viral load and CD4+ >500 cells/mm3. Peripheral T cell subsets were assessed by flow cytometry and plasma biomarkers by immunoassays.
Results |
HIV/HCV-coinfected patients had higher values of in IL-10, IL-4, IP-10, IL-8, IL-1β, IL-18, IL-6, IFN-γ, IL-12p70, TNF-α, sVCAM-1, sICAM-1, and sTNFR-1 than HIV control subjects, both at the beginning and at the end of follow-up. Moreover, three biomarkers (CD4+CD38+, telomere length, and IL-1RA) were normalized in relation to the control group at the end of follow-up (the HIV/HCV-b group had higher values and the HIV/HCV-f group had similar values as the HIV-group). Additionally, LPS, IL-2, and IL-17A levels were higher in the HIV/HCV-f group than the HIV-group (24 weeks after SVR). During the follow-up, HIV/HCV-coinfected patients had a significant decrease by the end of follow-up in CD8+CD45RA−CD28+, CD4+CD38+, CD4+CD25+CD127−/low, CD4+CD25+CD127−/low CD45RA−, FABP2, LBP, IP-10, sVCAM1. Only CD4+CD38+ was normalized.
Conclusion |
HIV/HCV-patients showed a slight improvement in the overall profile of immune biomarkers after achieving SVR.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic hepatitis C, HIV, HCV therapy, Biomarkers, Inflammation, Immune activation
Abbreviations : HIV, AIDS, cART, HCV, CHC, SVR, Tregs, Th, IFN, peg-IFNα+rib, DAAs, LSM, HIV/HCV-b-group, HIV/HCV-f-group, HIV-group, CDXX, IL-XX, IP-10, MCP-1, TNF-α, sICAM1, sVCAM1, sTNFR1, PAI-1, LPS, LBP, sCD14, FABP2, TGF-β, ST, GLM, p-value, adj-p-values, PLS-DA, AUROC, VIP, SF
Plan
Vol 80 - N° 1
P. 99-110 - janvier 2020 Retour au numéro
Article précédent
- Association between meteorological variations and activities of influenza A and B across different climate zones: a multi-region modelling analysis across the globe
- Ka Chun Chong, Tsz Cheung Lee, Seweryn Bialasiewicz, Jian Chen, David W. Smith, Wisely S.C. Choy, Mel Krajden, Hamid Jalal, Lance Jennings, Burmaa Alexander, Hong Kai Lee, Pieter Fraaij, Avram Levy, Apple C.M. Yeung, Sarah Tozer, Steven Y.F. Lau, Katherine M. Jia, Julian W.T. Tang, David S.C. Hui, Paul K.S. Chan
- Zika virus seroprevalence in blood donors from the Northeastern region of São Paulo State, Brazil, between 2015 and 2017
- Svetoslav Nanev Slavov, Rafael Rahal Guaragna Machado, Alexander Rodrigo Ferreira, Camila Pereira Soares, Danielle Bastos Araujo, Danielle Bruna Leal Oliveira, Dimas Tadeu Covas, Edison Luiz Durigon, Simone Kashima
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?